Sarepta Therapeutics, Inc. (NasdaqGS: SRPT)
Health Care · Biotechnology · US
$17.56
-1.62% today · -22.8% 1Y
Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.89B and employs 835 people.
Over the last twelve months the share price has lost 22.8%, trading between 14.68 and 24.68.
Tweenvest scores Sarepta Therapeutics, Inc. across four factors: quality 49/100, value 48/100, growth 100/100. Its strongest factor is growth.
SRPT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.89B
- Revenue (TTM)
- $1.97B
- P/E
- —
- EPS
- -1.32
- Dividend yield
- —
- Beta (5Y)
- 0.38
- 52-week high
- $24.68
- 52-week low
- $14.68
- Avg volume (3M)
- —
- Shares outstanding
- 105.63M
- Employees
- 835
- Next earnings
- —
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
- ISIN
- US8036071004
- Founded
- 1980
- Listed since
- Jun 4, 1997
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Jinyu Bio-technology Co., Ltd.SHSE: 600201 | $1.93B | CN¥11.84 | +1.98% |
| Pell Bio-Med Technology Co., Ltd.TWSE: 6949 | $1.92B | NT$46.85 | +5.28% |
| Lakefront Biotherapeutics NVENXTAM: LKFT | $1.92B | €26.32 | +1.70% |
| Agios Pharmaceuticals, Inc.NasdaqGS: AGIO | $1.90B | $31.10 | -2.23% |
| Voronoi, Inc.KOSDAQ: A310210 | $1.87B | ₩138,400.00 | -3.96% |
| Intellia Therapeutics, Inc.NasdaqGM: NTLA | $1.83B | $12.69 | -2.91% |
| Xencor, Inc.NasdaqGM: XNCR | $1.83B | $24.81 | +0.73% |
| Zymeworks Inc.NasdaqGS: ZYME | $1.83B | $25.41 | -1.47% |
Figures last refreshed Oct 11, 2026.